文献速递骨显像与常规 SPECT核素与放射性配体治疗放射性药物与辐射防护

177Lu-DOTA-IBA治疗骨转移的生物分布与剂量学研究

Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases.
PubMed 文献 · EJNMMI Res · 2024-03-22

这项前瞻性研究纳入5例多发骨转移患者,单次给予1110 MBq 177Lu-DOTA-IBA后7天内行全身平面及SPECT/CT显像并采血,评估生物分布与内照射剂量。结果显示骨病灶快速摄取并高滞留、血液清除快,主要器官吸收剂量在安全限值内,红骨髓为剂量限制器官,未见不良反应。

要点

  • 5例多发骨转移患者单次给予1110 MBq 177Lu-DOTA-IBA,7天内行SPECT/CT及采血评估。
  • 骨肿瘤病灶平均吸收剂量5.740 Gy/GBq,红骨髓0.095 Gy/GBq,为剂量限制器官。
  • 给药后未记录到不良反应,关键器官与全身吸收剂量在安全限值内。

核心结论

  • 剂量学结果显示关键器官与全身吸收剂量在安全限值内,且骨滞留高。
  • 177Lu-DOTA-IBA可能是靶向治疗骨转移、控制其进展并改善晚期骨转移患者生存与生活质量的有前景的放射性药物替代选择。

研究设计与样本

  • 前瞻性研究,纳入5例多发骨转移患者。
  • 患者接受1110 MBq 177Lu-DOTA-IBA后7天内行全身平面显像、SPECT/CT显像及静脉采血。
  • 对主要器官和肿瘤病灶进行剂量学评估,并用血液生物标志物评估安全性。

主要发现

  • 所有患者中177Lu-DOTA-IBA均表现为快速摄取、骨病灶高滞留和血液快速清除。
  • 该队列中骨肿瘤病灶、肾脏、肝脏、脾脏、红骨髓、膀胱壁和成骨细胞的平均吸收剂量分别为5.740、0.114、0.095、0.121、0.095和0.333 Gy/GBq。
  • 尽管没有患者达到预定剂量阈值,红骨髓仍将是剂量限制器官。
  • 给予1110 MBq 177Lu-DOTA-IBA后未记录到不良反应。

关键数值与推荐

  • 骨肿瘤病灶平均吸收剂量为5.740 Gy/GBq。
  • 肾脏平均吸收剂量为0.114 Gy/GBq,肝脏为0.095 Gy/GBq,脾脏为0.121 Gy/GBq。
  • 红骨髓平均吸收剂量为0.095 Gy/GBq,膀胱壁为0.095 Gy/GBq,成骨细胞为0.333 Gy/GBq。

临床怎么用

  • 原文结论认为177Lu-DOTA-IBA是靶向治疗骨转移的有前景的放射性药物替代选择,可控制其进展并改善晚期骨转移患者的生存与生活质量。
  • 原文指出红骨髓将是剂量限制器官,尽管本队列中没有患者达到预定剂量阈值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We designed and synthesized a novel bisphosphonate radiopharmaceutical (68 Ga- or 177Lu-labeled DOTA-ibandronate [68 Ga/177Lu-DOTA-IBA]) for the targeted diagnosis and treatment of bone metastases. The biodistribution and internal dosimetry of a single therapeutic dose of 177Lu-DOTA-IBA were evaluated using a series of single-photon emission computerized tomography (SPECT) images and blood samples. Five patients with multiple bone metastases were included in this prospective study. After receiving 1110 MBq 177Lu-DOTA-IBA, patients underwent whole-body planar, SPECT/CT imaging and venous blood sampling over 7 days. Dosimetric evaluation was performed for the main organs and tumor lesions. Safety was assessed using blood biomarkers. RESULTS: 177Lu-DOTA-IBA showed fast uptake, high retention in bone lesions, and rapid clearance from the bloodstream in all patients. In this cohort, the average absorbed doses (ADs) in the bone tumor lesions, kidneys, liver, spleen, red marrow, bladder-wall, and osteogenic cells were 5.740, 0.114, 0.095, 0.121, 0.095, and 0.333 Gy/GBq, respectively. Although no patient reached the predetermined dose thresholds, the red marrow will be the dose-limiting organ. There were no adverse reactions recorded after the administration of 1110 MBq 177Lu-DOTA-IBA. CONCLUSION: Dosimetric results show that the ADs for critical organs and total body are within the safety limit and with high bone retention. It is a promising radiopharmaceutical alternative for the targeted treatment of bone metastases, controlling its progression, and improving the survival and quality of life of patients with advanced bone metastasis.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Li H, Pei W, Yang X, et al. Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases. EJNMMI Res. 2024. PMID: 38517637. doi:10.1186/s13550-024-01094-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。